Does This Unopened Toxin Vial Need a Fridge Before Mixing?

Does this unopened toxin vial need a fridge?

When patients enter a treatment room for facial aesthetic injections, they frequently notice glass medication vials resting on the practitioner's prep counter, mayo stand, or procedural cart. Because FDA-approved aesthetic neuromodulators are often assumed to share one refrigerated unopened-storage rule, many patients then believe that any neuromodulator left out of a refrigerator is ruined, inactive, or counterfeit. This perception creates immediate anxiety: patients wonder whether their injector is negligent, whether the product will fail to relax targeted muscles, or whether unapproved grey-market drugs are being administered.

That anxiety stems from a foundational misunderstanding: treating the clinical refrigerator as a universal rule rather than reading the specific, FDA-approved prescribing information printed on each commercial carton. In modern aesthetic medicine, different neuromodulator formulations utilize distinct purification processes, excipient matrices, and thermal stabilizers. As a result, three distinct unopened storage identities exist under current United States labeling: refrigerator-required products, room-temperature-authorized products that do not require refrigeration, and dual-authorized products that permit either room-temperature shelf storage or refrigeration within their protective carton.

Furthermore, patients and administrative staff must never confuse unopened dry powder storage with the handling of reconstituted liquid solution. Before a vial is reconstituted, the botulinum neurotoxin exists as a sterile, vacuum-dried or lyophilized powder formulated with excipients like human serum albumin, sugars, or synthetic peptides. Once a clinician reconstitutes the powder with the labeled diluent—current US aesthetic toxin labels specify sterile, preservative-free 0.9% Sodium Chloride Injection, USP—the dry matrix becomes an aqueous solution. At that precise moment, a completely different, strict set of clinical rules governs the vial: single-patient use restrictions, mandatory refrigeration between 2°C and 8°C, and stringent 24-hour or 72-hour administration clocks. This guide focuses strictly on the first question: what does current FDA labeling require for an unopened vial before any diluent is added?

Identity worksheet: product, strength, unopened, and unknown fields

To determine whether an observed vial complies with manufacturer storage standards, clinicians and informed patients should use an objective, carton-by-carton verification workflow. Relying on memory or informal office habits often leads to mistaken assumptions—either unnecessarily discarding thermally stable products or improperly exposing cold-chain-dependent toxins to prolonged ambient warmth.

The evaluation worksheet requires six specific data fields, captured directly from the primary packaging:

1. Product Name as Printed: Record the exact commercial brand name and nonproprietary established name printed on the outer carton and primary vial label (for example, BOTOX Cosmetic / onabotulinumtoxinA, XEOMIN / incobotulinumtoxinA, or DAXXIFY / daxibotulinumtoxinA-lanm). Never assume interchangeable storage rules across brands.

2. Unit Strength if Printed: Note the labeled nominal unit potency. In the United States, aesthetic presentations are typically packaged in 50-unit or 100-unit single-dose vials, while certain therapeutic or alternative formulations appear in 200-unit or 300-unit presentations. Noting the unit count also serves as an immediate verification check against unapproved foreign formats.

3. Unopened Integrity Status: Confirm whether the vial remains in its factory-sealed state with an intact tamper-evident flip-off cap and unpunctured rubber septum, or whether the vial has already been reconstituted. Once reconstituted, unopened storage rules no longer apply.

4. Supported Labeled Storage Identity: Match the product to its authorized storage category under current US labeling: Refrigerator-Required (2°C to 8°C), Room-Temperature-Allowed Without Refrigeration (at or below 25°C), Room-Temperature or Refrigerated in Original Carton (20°C to 25°C or 2°C to 8°C), or Unmatched/Excursion.

5. Light Protection and Packaging Rules: Identify whether the prescribing information explicitly mandates storage within the original outer carton to protect the lyophilized protein from ambient ultraviolet or fluorescent light degradation.

6. Unresolved or Unknown Fields: Document transparently any missing data, unverified distributor sources, or illegible markings. If a vial lacks official US labeling, the product cannot be validated solely by placing it in a refrigerator.

graph TD
  Start["Inspect Unopened Toxin Package"] --> Integrity{"Is vial unpunctured with intact factory seal?"}
  Integrity -- "No (Reconstituted)" --> Leftover["Out of Scope for Unopened Worksheet<br/>(Follow 24-hr or 72-hr refrigerated leftover rules)"]
  Integrity -- "Yes (Unopened)" --> Identify["Identify Exact Printed Brand Name"]

  Identify --> BrandBotox["BOTOX Cosmetic<br/>(onabotulinumtoxinA)"]
  Identify --> BrandXeomin["XEOMIN<br/>(incobotulinumtoxinA)"]
  Identify --> BrandDaxxify["DAXXIFY<br/>(daxibotulinumtoxinA-lanm)"]
  Identify --> BrandOthers["Dysport / Jeuveau / Letybo"]
  Identify --> BrandUnknown["Missing Brand or Non-US Label"]

  BrandBotox --> StorageBotox["Refrigerator Required: 2°C to 8°C<br/>(Room temp is an unapproved excursion)"]
  BrandXeomin --> StorageXeomin["Room Temperature Allowed: ≤25°C<br/>(Refrigeration not required; optional)"]
  BrandDaxxify --> StorageDaxxify["Dual Storage: 20°C to 25°C OR 2°C to 8°C<br/>(Must remain in original carton to protect from light)"]
  BrandOthers --> StorageOthers["Refrigerator Required: 2°C to 8°C<br/>(Protect from light; do not freeze)"]
  BrandUnknown --> StorageUnknown["Mark as UNKNOWN<br/>(Fridge storage does not prove authenticity)"]

To illustrate how these criteria function in real-world clinical observation, the following worksheet maps eleven hypothetical carton scenarios. These worked examples represent specific packaging presentations and storage environments without referencing any actual clinic lot, audit record, or patient case:

As demonstrated by this classification matrix, evaluating storage compliance requires checking the brand name against its specific FDA-approved prescribing information rather than applying an arbitrary single-rule assumption across all aesthetic treatments.

BOTOX Cosmetic: unopened vials are labeled for the refrigerator

BOTOX Cosmetic (onabotulinumtoxinA), manufactured by AbbVie / Allergan Aesthetics, has an official United States Prescribing Information revised October 2024 (BLA 103000). Section 16 (How Supplied/Storage and Handling) is unambiguous on unopened storage:

This explicit language establishes that cold-chain refrigeration between 2°C and 8°C is the only authorized storage condition for unopened BOTOX Cosmetic. The product is supplied as sterile, vacuum-dried powder in single-dose glass vials containing either 50 Units (NDC 0023-3919-50) or 100 Units (NDC 0023-9232-01). Both the primary vial label and outer carton prominently feature the established name OnabotulinumtoxinA and the United States License number 1889.

The October 2024 PI describes BOTOX Cosmetic as a vacuum-dried purified botulinum toxin type A complex consisting of the neurotoxin and several accessory proteins, supplied without a preservative. Each 50-unit vial contains 0.25 mg of Albumin Human and 0.45 mg of sodium chloride; each 100-unit vial contains 0.5 mg of Albumin Human and 0.9 mg of sodium chloride. Those listed ingredients explain the formulation on the label; they do not create a remaining-potency clock after an unlabeled room-temperature excursion, and the PI does not authorize unopened room-temperature storage.

Two common misconceptions surround BOTOX Cosmetic storage:

• The room-temperature excursion myth: Informal blogs and vendor sites sometimes claim that unopened BOTOX Cosmetic can sit at room temperature for days without loss of potency. the FDA-approved prescribing information does not authorize room-temperature shelf storage. Leaving an unopened vial at ambient temperature on a clinic counter represents an unauthorized handling excursion. If an excursion occurs, practices must quarantine the affected product and consult the manufacturer's medical information department rather than assuming off-label stability.

• The historical freezer option: Older onabotulinumtoxinA package inserts listed freezer storage as an option. Current BOTOX Cosmetic labeling revised in October 2024 specifies unopened refrigeration between 2°C and 8°C and does not restore freezer language as the unopened rule. Practices should follow the in-force PI rather than retired text.

Once an unopened vial of BOTOX Cosmetic is reconstituted with sterile, preservative-free 0.9% sodium chloride, the labeled parameters become even stricter. Reconstituted BOTOX Cosmetic must be stored in a refrigerator at 2°C to 8°C and administered within 24 hours. The label explicitly instructs: "Do not freeze reconstituted BOTOX Cosmetic." Any remaining solution must be discarded after the treatment session in accordance with institutional biohazard standards.

XEOMIN: refrigeration of unopened vials is not required

When patients see a sealed vial of XEOMIN (incobotulinumtoxinA) sitting on an ambient treatment counter at 21°C or 22°C, the instinct is often to treat it as mishandled BOTOX Cosmetic. That is the wrong identity. Unopened XEOMIN has a different labeled storage rule.

Under the in-force United States Food and Drug Administration labeling for BLA 125360 (Supplement S-108, revised June 2026), Section 16 states unequivocally:

Merz Aesthetics' professional Using XEOMIN page restates the PI: no refrigeration is required prior to reconstitution, and unopened vials should be stored at or below 25°C (77°F). An unopened XEOMIN vial on a counter at or below 25°C is not, by itself, out of labeled unopened storage. That labeled identity is not a remaining-potency assay and is not proof the vial is authentic.

The June 2026 PI describes how the botulinum toxin complex is purified and the active ingredient is separated from hemagglutinins and non-hemagglutinins through a series of steps, yielding a 150 kDa neurotoxin without accessory proteins. One vial contains 50, 100, or 200 Units of incobotulinumtoxinA, human albumin (1 mg), and sucrose (4.7 mg). Those listed facts support the labeled unopened range; they are not a finding that a given vial has retained potency, and they do not make XEOMIN interchangeable with BOTOX Cosmetic or DAXXIFY units.

Key operational points regarding XEOMIN storage include:

• Can XEOMIN be stored in a refrigerator? Yes. The prescribing information specifies that refrigeration is not required, but it is not forbidden. Storing unopened XEOMIN in a medical refrigerator between 2°C and 8°C remains fully compliant because 2°C to 8°C is strictly within the parameter of 'at or below 25°C.' Many busy aesthetic clinics choose to store all neuromodulators in a central refrigerator simply to standardize daily staff routines and maintain consolidated inventory control.

• Retired freezer language: In earlier FDA approval documents from 2010 through 2015, XEOMIN labeling explicitly listed room temperature, refrigeration, and freezer storage as three distinct acceptable options for unopened vials. In modern labeling (including supplement 125360s108), the FDA streamlined this phrasing to 'at or below 25°C (77°F)' while retaining the explicit clarification that refrigeration is not required. Practices should not cite retired historical text.

• The reconstitution dividing line: The moment sterile saline is injected into a XEOMIN vial, its room-temperature stability terminates immediately. The June 2026 prescribing information mandates that reconstituted XEOMIN must be refrigerated at 2°C to 8°C for up to 24 hours until time of use, administered for only one injection session and for only one patient, with all unused solution safely discarded.

Understanding XEOMIN's labeled room-temperature allowance prevents unnecessary disputes in clinic reception areas and reassures patients that clinical science—not corner-cutting—governs how their medication is staged before treatment. For an in-depth clinical comparison of dosing units and indications, consult our companion analysis on Xeomin vs Botox: Same 20/24/40/64-Unit Upper Face, Different US Labels and our patient-focused Xeomin (IncobotulinumtoxinA): What It Is, How It Works, and What to Expect.

DAXXIFY: unopened vials may be room temperature or refrigerated

DAXXIFY (daxibotulinumtoxinA-lanm), developed by Revance Therapeutics, represents a third distinct regulatory storage category. Under its in-force DailyMed labeling (revised November 2023) and FDA approval documents (BLA 761127), Section 16 authorizes dual storage options:

Under this labeled standard, both places can be labeled-correct when the other conditions are met. An unopened DAXXIFY vial at 20°C to 25°C in the original carton is within labeled unopened storage. An unopened DAXXIFY vial refrigerated at 2°C to 8°C in the original carton is also within labeled unopened storage. The PI does not rank those two options.

However, DAXXIFY's prescribing information includes a critical, non-negotiable packaging requirement that is frequently overlooked: the product must remain in its original carton to protect from light. DailyMed lists no human albumin in DAXXIFY. Each vial contains daxibotulinumtoxinA-lanm with L-histidine, L-histidine HCl monohydrate, polysorbate 20, RTP004 peptide (a 35-amino-acid excipient that the PI says prevents surface adsorption and promotes thermal stability), and trehalose dihydrate. The PI does not define an unlabeled light-exposure clock. A bare unopened vial left out of its carton is outside the labeled carton-and-light instruction. DAXXIFY's room-temperature option is the 20°C to 25°C band in the original carton, not any ambient shelf; a carton stored at 15°C would be outside both the 20°C to 25°C band and the 2°C to 8°C refrigerator band. XEOMIN's unopened rule is broader ('at or below 25°C').

DAXXIFY also differs significantly from other neuromodulators in its post-reconstitution handling window:

• Extended 72-hour reconstituted window: While BOTOX Cosmetic and XEOMIN specify that reconstituted solution must be administered within 24 hours, the DAXXIFY prescribing information explicitly allows administration within 72 hours after reconstitution, provided the unused solution is stored refrigerated between 2°C and 8°C, kept protected from light, and never frozen.

• Single-patient boundary preserved: Although the reconstituted stability window extends to 72 hours, DAXXIFY vials are supplied as single-dose presentations (50 Units or 100 Units). The extended clock exists for procedural flexibility, not as an authorization to perform multi-patient vial sharing across several days without strict aseptic single-patient isolation.

For a comprehensive examination of peptide formulation science and clinical persistence, review our detailed guide on Daxxify vs Botox: what's actually different, and who it's for. and clinical evidence regarding How Long Does Daxxify Last? Duration, Onset, and What to Expect.

Other US neurotoxins: Dysport, Jeuveau, and Letybo storage profiles

To avoid treating every carton as XEOMIN or DAXXIFY, patients and clinicians should also mark the other currently labeled US toxins that remain fridge-required when unopened:

• DYSPORT (abobotulinumtoxinA): Under DailyMed labeling (revised September 2023), unopened vials of DYSPORT must be stored refrigerated between 2°C and 8°C (36°F to 46°F) and protected from light. Once reconstituted, unused DYSPORT may be stored in the original container, refrigerated at 2°C to 8°C, protected from light, for up to 24 hours; do not freeze reconstituted DYSPORT. DYSPORT is supplied in 300-unit and 500-unit vials. Those strengths are identity fields, not a reconstitution recipe.

• JEUVEAU (prabotulinumtoxinA-xvfs): Under DailyMed labeling (revised April 2023), unopened vials of JEUVEAU should be stored in a refrigerator between 2°C and 8°C (36°F to 46°F) in the original carton to protect from light. The principal display panel on both carton and vial prominently states 'DO NOT FREEZE.' Reconstituted solution must be refrigerated in the original carton and administered within 24 hours.

• LETYBO (letibotulinumtoxinA-wlbg): Approved under BLA 761225, with DailyMed labeling issued February 2024, unopened LETYBO vials should be stored in a refrigerator between 2°C and 8°C (36°F to 46°F) in the original carton to protect from light. The label carries an explicit 'Do not freeze' instruction. Following reconstitution, unused product must be kept refrigerated in the original carton and administered within 24 hours.

• Therapeutic BOTOX (onabotulinumtoxinA): The therapeutic presentation of BOTOX (used for medical indications such as cervical dystonia, spasticity, chronic migraine, and hyperhidrosis) also mandates unopened storage in a refrigerator between 2°C and 8°C for up to 36 months under its official package insert.

In summary, current US labeling does not give every unopened toxin the same fridge rule: unopened XEOMIN is labeled at or below 25°C with refrigeration not required. Unopened DAXXIFY may be stored at 20°C to 25°C or refrigerated at 2°C to 8°C, in the original carton to protect from light. Unopened BOTOX Cosmetic, Dysport, Jeuveau, Letybo, and therapeutic BOTOX are fridge-required at 2°C to 8°C. Those are separate identities, not a ranking, and they are not proof of authenticity.

Room temperature is not a counterfeit test

In April 2024, the United States Food and Drug Administration issued an urgent nationwide public safety alert regarding counterfeit versions of Botox identified in multiple states. These illicit, unapproved products were administered in non-medical med spa environments, leading to severe adverse events, including blurred vision, dysphagia, respiratory distress, and hospitalizations characteristic of botulism poisoning.

This alert heightened patient awareness and prompted individuals to scrutinize product handling in medical offices. However, it also created a hazardous misconception: the belief that physical storage temperature serves as an indicator of drug authenticity.

To verify whether an injectable product is authentic and legal, patients and clinicians must rely on documented regulatory identifiers rather than whether the glass feels cold to the touch:

• FDA-Approved Presentation Sizes: Authentic BOTOX Cosmetic is manufactured by AbbVie only in 50-unit and 100-unit single-dose vials. Therapeutic BOTOX is approved in 100-unit and 200-unit vials. In the April 2024 counterfeit alert, the FDA specifically identified illicit cartons labeled as "150 Units"—a presentation size AbbVie/Allergan do not make for BOTOX or BOTOX Cosmetic. A carton marked 150 Units is not an FDA-approved BOTOX or BOTOX Cosmetic presentation and was one of the suspect identifiers in that alert; room temperature is not that identifier.

• Proper Active Ingredient Naming: Authentic packaging displays the established biological name capitalized as OnabotulinumtoxinA on both the outer carton and the inner vial label. Counterfeit packaging often misspells this established name, omits it entirely, or substitutes vague language like 'Botulinum Toxin Type A.'

• U.S. License Number Verification: Genuine Allergan/AbbVie packaging features U.S. License number 1889 on both the outer carton and the primary container label. Illicit versions frequently omit this licensing mark or list incorrect manufacturing entities.

• Authenticity and supply-chain checks, not temperature: Serialization, authorized trading partners, and lot matching are authenticity and supply-chain jobs, not a temperature test. For those checks, see Counterfeit Botox and Fillers — How to Verify Your Injector Uses Authentic Products and our analysis of Counterfeit Botox and Diverted Filler: How Clinics Verify Authentic Supply.

• Authorized Wholesale Distribution Channels: Legitimate aesthetic practices purchase medications directly from the licensed manufacturer (e.g., Allergan Aesthetics/AbbVie, Merz Aesthetics, Revance Therapeutics, Galderma, Evolus) or authorized wholesale distributors. Practices that purchase heavily discounted injectables from unauthorized internet brokers, overseas pharmacies, or grey-market resellers risk receiving adulterated or lethal counterfeit lots. Review our regulatory report on FDA's First DSCSA Warning Letter to a Med Spa: What Aesthetic Practices Must Do Now to see how enforcement agencies investigate illegal distribution networks.

What this page does not decide

To maintain clinical integrity and protect patient safety, this guide establishes clear informational boundaries. This article is strictly a packaging and storage identification worksheet; it intentionally does not decide, authorize, or provide instructions for the following clinical activities:

• No reconstitution or mixing recipes: This guide does not instruct clinicians or patients on how to reconstitute neuromodulators, what volume of preservative-free 0.9% Sodium Chloride Injection to add, or how to dilute powder. Dilution ratios vary by anatomical area, muscle mass, and provider technique. Neuromodulators must be reconstituted only by licensed, qualified medical professionals in accordance with approved labeling.

• No unit conversion or interchangeability formulas: Botulinum toxin units are biological assay measurements specific to each manufacturer's proprietary testing method. They are not interchangeable between products. Twenty units of BOTOX Cosmetic do not equate to twenty units of Dysport, and dosing ratios cannot be calculated from a storage table. For detailed comparative analyses of clinical profiles, explore our guides on Types of Botox in 2026: Every FDA-Approved Neurotoxin, Compared and Baby Botox vs Regular Botox: Dose Philosophy, Not a Different Drug.

• No multi-patient vial sharing protocols: Single-dose vials are approved for single-patient, single-procedure use. Dividing remaining liquid from a single-dose vial across multiple patients introduces substantial infection control hazards and documentation complexities. Practices seeking audit-ready log templates should consult our Botox Vial Log Workflow: Lot Numbers, Storage, Wastage, and Audit Readiness and our clinical Injectable Charting Template: Facial Map, Units, Lot Numbers, and Follow-Up.

• No product ranking or superiority endorsements: The fact that XEOMIN does not require refrigeration or that DAXXIFY permits room-temperature storage in its carton does not make either product superior to BOTOX Cosmetic, Dysport, Jeuveau, or Letybo. Storage characteristics reflect molecular formulation and excipient design, not clinical efficacy, safety superiority, or patient satisfaction.

• No off-label excursion authorization: If an unopened vial of BOTOX Cosmetic or another refrigerated toxin has been accidentally left at room temperature for several hours or days, this guide does not authorize its use. Only the manufacturer's medical information department can evaluate lot-specific stability data following a temperature excursion.

• No self-treatment or unlicensed injection: Botulinum neurotoxins are high-potency prescription biologics with boxed warnings regarding distant spread of toxin effects, respiratory impairment, and dysphagia. Review our guide on Boxed warnings and contraindications: what FDA injectable labels actually say. Botulinum toxin products are prescription biologics; they are not a self-treatment worksheet. Patients should review How to choose an injector: credentials, supervision, red flags, and what to ask. and learn how to request their official Requesting Aesthetic Records: Device Settings, Lot Numbers, and Limits.

Sources

The storage classifications, regulatory standards, and packaging requirements documented in this guide are derived from the following primary FDA-approved prescribing information documents, DailyMed structured product labeling records, and regulatory safety alerts:

• BOTOX Cosmetic (onabotulinumtoxinA) Prescribing Information (revised October 2024). AbbVie Inc. Official US prescribing information detailing unopened vial storage at 2°C to 8°C (36°F to 46°F), 50- and 100-unit single-dose presentations, US License 1889, and 24-hour reconstituted refrigerated handling.

• DailyMed: BOTOX COSMETIC (onabotulinumtoxinA) injection, powder, lyophilized, for solution. U.S. National Library of Medicine. Current structured product labeling affirming refrigerated unopened storage and packaging specifications.

• FDA label: BOTOX Cosmetic (onabotulinumtoxinA), BLA 103000 (2024). U.S. Food and Drug Administration. Regulatory label specifying cold-chain storage parameters and single-dose vial standards.

• FDA label: XEOMIN (incobotulinumtoxinA), BLA 125360/S-108 (revised June 2026). U.S. Food and Drug Administration. In-force prescribing information establishing that unopened vials are stored at or below 25°C (77°F) and that refrigeration of unopened vials is not required.

• Using XEOMIN: dosing and administration (professional). Merz Aesthetics. Manufacturer clinical documentation confirming room-temperature storage prior to reconstitution and 24-hour reconstituted refrigerated handling.

• DailyMed: DAXXIFY (daxibotulinumtoxinA-lanm) injection, powder, lyophilized, for solution. U.S. National Library of Medicine. In-force structured product labeling authorizing unopened storage at room temperature 20°C to 25°C or refrigerated 2°C to 8°C in original carton, alongside 72-hour reconstituted refrigerated handling.

• FDA label: DAXXIFY (daxibotulinumtoxinA-lanm), BLA 761127 (2022). U.S. Food and Drug Administration. Approval labeling detailing dual unopened storage and light-protection carton requirements.

• DailyMed: DYSPORT (abobotulinumtoxinA) injection, powder, lyophilized, for solution. U.S. National Library of Medicine. Prescribing information requiring unopened refrigeration between 2°C and 8°C and light protection.

• DailyMed: JEUVEAU (prabotulinumtoxinA-xvfs) powder. U.S. National Library of Medicine. Product labeling mandating refrigerated storage between 2°C and 8°C in original carton and prohibiting freezing.

• DailyMed: LETYBO (letibotulinumtoxinA-wlbg) injection, powder, lyophilized, for solution. U.S. National Library of Medicine. Labeling mandating refrigerated storage between 2°C and 8°C in original carton and prohibiting freezing.

• BOTOX (onabotulinumtoxinA) Prescribing Information. AbbVie Inc. Therapeutic prescribing information specifying refrigerated unopened storage between 2°C and 8°C.

• Counterfeit Version of Botox Found in Multiple States. U.S. Food and Drug Administration. Drug safety communication outlining carton markings, unapproved 150-unit presentations, and supply chain verification.